迅速血漿反応検査の市場規模、シェア、成長分析：検体別、検査タイプ別、用途別、エンドユーザー別、地域別-産業予測、2025～2032年

世界の迅速血漿反応検査の市場規模は、2023年に28億米ドルと評価され、2024年の30億9,000万米ドルから2032年には67億7,000万米ドルに成長し、予測期間（2025～2032年）のCAGRは10.3％で成長する見通しです。

男性同性愛者や妊婦などの高リスク集団における梅毒発症率の上昇により、迅速血漿反応検査の需要が大幅に増加しています。これらの検査システムにおける技術の進歩は、合理化されたサンプル処理を容易にし、スループットを向上させるため、大量検査を行う検査室にとって特に有益です。さらに、性感染症（STI）スクリーニングに焦点を当てた政府の取り組みが、市場の成長をさらに刺激すると予想されます。また、迅速な結果によるポイントオブケア（POC）検査への嗜好の高まりも、特に梅毒やその他のSTIに対する認識が高まっている新興市場での採用を促進すると思われます。しかし、リソースの限られた地域でのアクセスの制限、代替診断法との競争、そして規制上のハードルといった課題が、市場への浸透を2032年以降も妨げる可能性があります。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次・一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の展望
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と展望

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

迅速血漿反応検査市場規模：検体別、CAGR（2025～2032年）

• 市場概要
• 血液
• 血清
• プラズマ

迅速血漿反応検査市場規模：検査タイプ別、CAGR（2025～2032年）

• 市場概要
• 従来型検査
• 迅速検査

迅速血漿反応検査市場規模：用途別、CAGR（2025～2032年）

• 市場概要
• 診断
• スクリーニング

迅速血漿反応検査市場規模：エンドユーザー別、CAGR（2025～2032年）

• 市場概要
• 病院・診療所
• 診断検査室
• 研究機関

迅速血漿反応検査市場規模：地域別、CAGR（2025～2032年）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022～2024年）

主要企業プロファイル

• Thermo Fisher Scientific Inc.（USA）
• Danaher Corporation（USA）
• Abbott Laboratories（USA）
• F. Hoffmann-La Roche AG（Switzerland）
• Siemens Healthineers AG（Germany）
• Bio-Rad Laboratories, Inc.（USA）
• Merck KGaA（Germany）
• Quest Diagnostics（USA）
• Cardinal Health, Inc.（USA）
• bioMerieux SA（France）
• Becton, Dickinson and Company（BD）（USA）
• Sekisui Diagnostics（USA）
• Meridian Bioscience, Inc.（USA）
• Arlington Scientific Inc.（USA）
• Immunostics Inc.（USA）
• Novacyt Group（France）
• Trinity Biotech plc（Ireland）
• Atlas Medical GmbH（Germany/UK）
• Sclavo Diagnostics International S.r.l.（Italy）

結論と提言

Global Rapid Plasma Reagin Test Market size was valued at USD 2.8 billion in 2023 and is poised to grow from USD 3.09 billion in 2024 to USD 6.77 billion by 2032, growing at a CAGR of 10.3% during the forecast period (2025-2032).

The rising incidence of syphilis, particularly among high-risk populations such as men who have sex with men and pregnant women, is significantly increasing the demand for rapid plasma reagin tests. Technological advancements in these testing systems facilitate streamlined sample processing and enhance throughput, making them particularly beneficial for high-volume laboratories. Additionally, government initiatives focused on sexually transmitted infection (STI) screening are expected to further stimulate market growth. The growing preference for point-of-care (POC) testing due to quick results will also drive adoption, especially in emerging markets where awareness of syphilis and other STIs is on the rise. However, challenges like limited access in low-resource settings, competition from alternative diagnostics, and regulatory hurdles may hinder market penetration through 2032 and beyond.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Rapid Plasma Reagin Test market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Rapid Plasma Reagin Test Market Segments Analysis

Global Rapid Plasma Reagin Test Market is segmented by Specimen, Test Type, Application, End User and region. Based on Specimen, the market is segmented into Blood, Serum and Plasma. Based on Test Type, the market is segmented into Traditional Tests and Rapid Tests. Based on Application, the market is segmented into Diagnostics and Screening. Based on End User, the market is segmented into Hospitals & Clinics, Diagnostic Laboratories and Research Institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Rapid Plasma Reagin Test Market

The Global Rapid Plasma Reagin (RPR) Test market is experiencing significant growth driven by the rising prevalence of chronic diseases and a heightened awareness of health and wellness. This surge in demand for preventive healthcare is rooted in the critical need for early syphilis detection through routine screenings, which prevents complications and limits the infection's spread. Healthcare providers are increasingly incorporating RPR testing into standard preventive care practices, particularly for high-risk populations. This proactive strategy supports overarching public health initiatives aimed at lowering sexually transmitted infection (STI) rates and encourages regular screenings to promote better health outcomes.

Restraints in the Global Rapid Plasma Reagin Test Market

The Global Rapid Plasma Reagin Test market faces obstacles due to various biological factors, including autoimmune disorders and other infections, which can trigger non-specific reactions and yield inaccurate results. This often necessitates additional confirmatory testing, potentially delaying both diagnosis and treatment. Such limitations can undermine the perceived reliability of the rapid plasma reagin test among healthcare professionals, prompting them to favor alternative diagnostic approaches. As a result, this reluctance may hinder the broader acceptance and utilization of rapid plasma reagin tests, ultimately affecting their long-term presence in the market.

Market Trends of the Global Rapid Plasma Reagin Test Market

The Global Rapid Plasma Reagin (RPR) Test market is witnessing a significant trend towards the integration of RPR testing within multiplex diagnostic platforms, streamlining STI screening processes. This innovative approach facilitates the simultaneous detection of various infections such as HIV, syphilis, and hepatitis from a single sample, thereby reducing both testing time and associated costs. Particularly beneficial in resource-limited settings, this trend enhances logistical efficiency and promotes broader RPR adoption. By embedding RPR into comprehensive diagnostic strategies, the market is not only improving STI management but also significantly expanding overall diagnostic coverage, ultimately contributing to better public health outcomes globally.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Rapid Plasma Reagin Test Market Size by Specimen & CAGR (2025-2032)

• Market Overview
• Blood
• Serum
• Plasma

Global Rapid Plasma Reagin Test Market Size by Test Type & CAGR (2025-2032)

• Market Overview
• Traditional Tests
• Rapid Tests

Global Rapid Plasma Reagin Test Market Size by Application & CAGR (2025-2032)

• Market Overview
• Diagnostics
• Screening

Global Rapid Plasma Reagin Test Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals & Clinics
• Diagnostic Laboratories
• Research Institutes

Global Rapid Plasma Reagin Test Market Size & CAGR (2025-2032)

• North America (Specimen, Test Type, Application, End User)
  • US
  • Canada
• Europe (Specimen, Test Type, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Specimen, Test Type, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Specimen, Test Type, Application, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Specimen, Test Type, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Thermo Fisher Scientific Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quest Diagnostics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cardinal Health, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bioMerieux SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (BD) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sekisui Diagnostics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Meridian Bioscience, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Arlington Scientific Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Immunostics Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novacyt Group (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Trinity Biotech plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Atlas Medical GmbH (Germany/UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sclavo Diagnostics International S.r.l. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations